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Abstract
Objectives. To compare body composition in PsA with metabolic disease free (MDF) controls and type 2 diabetes
and assess body-composition predicted propensity for cardiometabolic disease.
Methods. Detailed MRI body composition profiles of 26 PsA participants from the IMAPA study were compared
with 130 age, sex and BMI-matched MDF controls and 454 individuals with type 2 diabetes from UK Biobank. The
body-composition predicted propensity for coronary heart disease (CHD) and type 2 diabetes was compared be-
tween PsA and matched MDF controls.
Results. PsA participants had a significantly greater visceral adipose tissue (VAT) volume [mean 5.89 l (S.D. 2.10 l)] com-
pared with matched-MDF controls [mean 4.34 l (S.D. 1.83 l)] (P <0.001) and liver fat percentage [median 8.88% (inter-
quartile range 4.42–13.18%)] compared with MDF controls [3.29% (1.98–7.25%)] (P <0.001). These differences
remained significant after adjustment for age, sex and BMI. There were no statistically significant differences in VAT,
liver fat or muscle fat infiltration (MFI) between PsA and type 2 diabetes. PsA participants had a lower thigh muscle vol-
ume than MDF controls and those with type 2 diabetes. Body composition-predicted propensity for CHD and type 2 dia-
betes was 1.27 and 1.83 times higher, respectively, for PsA compared with matched-MDF controls.
Conclusion. Individuals with PsA have an adverse body composition phenotype with greater visceral and ectopic
liver fat and lower thigh muscle volume than matched MDF controls. Body fat distribution in PsA is more in keep-
ing with the pattern observed in type 2 diabetes and is associated with greater propensity to cardiometabolic dis-
ease. These data support the need for greater emphasis on weight loss in PsA management to lessen CHD and
type 2 diabetes risk.
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Introduction
Increased BMI is strongly associated with PsA [1].
However, BMI is a global adiposity marker, and does
not capture regional fat. Central obesity, assessed
increased waist circumference, is independently
associated with higher odds of psoriasis [2]. The site of
fat storage is important as visceral adipose tissue (VAT)
and ectopic fat including fat in the liver and skeletal
muscle are associated with increased metabolic risk
[3, 4].
Body composition profiling with MRI allows detailed
assessment of body fat distribution including quantifica-
tion of abdominal subcutaneous adipose tissue (ASAT),
VAT, ectopic fat including liver fat and muscle fat infiltra-
tion (MFI), as well as fat-free thigh muscle volume
(FFMV). Higher VAT and MFI have been associated
with greater coronary heart disease (CHD) and type 2
diabetes prevalence, and higher liver fat with type 2 dia-
betes, independently of BMI [5]. Greater MFI and lower
FFMV may assist in the diagnosis of sarcopenia [6], for
which there are currently few data available in PsA.
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We aimed to characterize for the first time the detailed
body composition profile of PsA using MRI compared
with age, sex and BMI-matched metabolic disease free
(MDF) controls and type 2 diabetes, and to relate body
composition to propensity for CHD and type 2 diabetes
in PsA vs MDF controls.
Methods
Study design and participants
PsA participants were recruited from the Immune
Metabolic Associations in PsA (IMAPA) study. This open
label mechanistic study investigated cardiometabolic
outcomes in psoriatic disease treated with apremilast
[7]. PsA participants were required to fulfill the
Classification for PsA (CASPAR) criteria [8] and Scottish
Medicines Consortium guidelines for apremilast [9].
Exclusion criteria included other autoimmune rheumatic
diseases, severe renal disease, transaminitis > four
times upper limit of normal, significant recent weight
loss, pregnancy, insulin-dependent diabetes, and bio-
logic/leflunomide treatment. Between June 2017 and
November 2019, 29 PsA participants underwent body
composition profiling with a 3.0-T MRI scanner (Prisma,
Siemens, Erlangen, Germany) at baseline prior to start-
ing apremilast. After excluding three participants with
type 2 diabetes, body composition data from 26 PsA
participants were compared with 130 age, sex and BMI-
matched MDF controls from UK Biobank [10], a large,
general population-based cohort of 502 682 participants
aged 40–70 years, which included MR imaging of 10 000
individuals using a 1.5-T MRI scanner (Aera, Siemens,
Erlangen, Germany). MDF was defined as per Linge
et al. [5] and excluded individuals with cardiovascular
disease, diabetes, liver disease, respiratory, gastrointes-
tinal, and neurological conditions, cancers, RA, PsA,
and additionally psoriasis. Healthy controls were
matched 1:5, first on sex and then by choosing the
nearest MDF participants to each case using age
(65years) and BMI (62kg/m2). Distance was calculated
as the Euclidean distance and matching was done with-
out replacement. PsA imaging data was also compared
with UK Biobank participants with type 2 diabetes
(n¼454), defined as self-report of diabetes diagnosed
by a doctor and age at diagnosis 30 years.
Outcomes
A body composition profile (BCP) was defined as a
combination of variables that together described the fat
and/or muscle distribution of a group and included VAT
volume (l); VATindex (VAT normalized by height
squared); ASAT volume (L); ASATindex (ASAT normal-
ized by height squared); liver fat (%); MFI (%); thigh fat-
free muscle volume (FFMV); FFMV corrected for height
and compared with a sex- and BMI-matched virtual
control group (FFMVVCG) (unit: number of S.D.s from
mean value of VCG); and weight-to-muscle-ratio (kg/l).
These data, or derivations, were then plotted in six-axis
radar charts (body composition profile plots) as
described previously [5]. All participants underwent
standardized imaging protocols with analyses read in a
blinded fashion. Between MR scanner bias and reprodu-
cibility coefficients have been recently published by
AMRA Medical AB, Linkoping, Sweden [11]. The propen-
sity for CHD or type 2 diabetes based on body compos-
ition was calculated according to the method described
by Linge et al. [12]. For each PsA participant, the pro-
pensity for these conditions was estimated by the
prevalence of CHD and type 2 diabetes within personal-
ized control groups from UK Biobank matched for sex
and body fat distribution (VAT index, ASAT index, liver
fat and MFI) by applying the adaptive k-nearest neigh-
bours algorithm.
Statistical analysis
All analyses were performed using R version 3.4.4 (The
R Foundation, Vienna, Austria). Continuous data pre-
sented as mean (S.D.), except liver fat presented as me-
dian and interquartile range (IQR); categorical data
presented as number (n) and percentage (%). Body
composition in PsA was compared with age, sex and
BMI-matched MDF controls using mixed effects linear
regression and to type 2 diabetes using linear regres-
sion. Analyses were further adjusted for age, sex and
BMI. The difference in distributions of variables used for
matching (age and BMI) between PsA and matched
MDF controls were tested using Wilcoxon signed-rank
test. Body-composition predicted CHD and type 2 dia-
betes propensities were compared between PsA and
MDF controls using Wilcoxon signed-rank test.
The IMAPA study received ethical approval from West
of Scotland Research Ethics Committee 4 (Reference
17/WS/0006). The UK Biobank study was approved by
Rheumatology key messages
. PsA patients have greater visceral and ectopic liver fat, and lower thigh-muscle volume, than metabolic-disease-
free controls.
. This adverse body fat distribution is associated with greater propensity to type 2 diabetes and CHD.
. This study supports the need for weight loss interventions in PsA to lessen cardiometabolic risk.
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the North West Multicentre Ethics Research Committee
(Application Number 6569). All participants provided
written informed consent for data collection and
analysis.
Results
PsA participants were well matched for age and sex
with MDF controls but were younger and included a
greater proportion of females compared with type 2 dia-
betes participants (Table 1). There was no statistically
significant difference in BMI between PsA, MDF controls
and type 2 diabetes. Detailed characteristics of PsA par-
ticipants including baseline disease activity and cardio-
metabolic parameters are outlined in supplementary
Table S1, available at Rheumatology online.
PsA participants had a significantly greater VAT vol-
ume [mean 5.89 l (S.D. 2.10 l)] compared with matched
MDF controls [4.34 L (S.D. 1.83 l)] (P <0.001), and liver fat
percentage [median 8.88% (IQR 4.42–13.18%)] com-
pared with matched MDF controls [3.29% (1.98–7.25%)]
(P <0.001) (Table 1, Fig. 1A). These differences per-
sisted after adjustment for age, sex and BMI. There
were no statistically significant differences in VAT, liver
fat or MFI between PsA and type 2 diabetes (Table 1,
Fig. 1B). PsA participants had lower FFMV and
FFMVVCG, and greater weight-to-muscle-ratio than MDF
controls and type 2 diabetes participants after adjust-
ment (Table 1), indicating lower thigh muscle volume in
PsA (Table 1).
The distribution of body-composition predicted pro-
pensity for CHD and type 2 diabetes for PsA partici-
pants (red) in relation to the complete UK Biobank
dataset (grey) is outlined in supplementary Fig. S1, avail-
able at Rheumatology online, together with mean dis-
ease propensities. PsA participants had 1.27 times
higher mean CHD propensity and 1.83 times higher
mean type 2 diabetes propensity compared with their
matched MDF controls suggestive of a body compos-
ition phenotype with stronger association to type 2
diabetes.
Discussion
This is the first study to demonstrate PsA has an ad-
verse body fat distribution compared with healthy con-
trols and which is more in line with type 2 diabetes on
MRI with evidence of elevations in VAT and liver fat.
Such findings, in turn, predict greater CHD and type 2
diabetes propensity, by 27% and 83% respectively,
compared with MDF controls. PsA participants also had
lower thigh muscle volume than MDF controls and type
2 diabetes participants.
Previous studies showed greater mean total body fat
in PsA (46% 6 S.D. 5.7%) compared with healthy con-
trols (43.4% 6 5.5%) (P ¼0.04); however, individual fat
compartments were not measured [13]. One prior study
using CT has reported greater visceral fat in psoriasis
compared with age- and sex-matched controls [14], but
there was no data on liver fat. Our finding of higher liver
fat fraction in PsA fits with increased Non-Alcoholic














Age (years) 56.0 (9.0) 57.4 (6.5) 0.766 — 65.4 (6.9) < 0.001 —
Female (n, %) 13 (50) 65 (50) 1.000 — 158 (34.8) <0.001 —
BMI (kg/m2) 31.2 (6.4) 30.5 (5.3) 0.799 — 29.9 (5.2) 0.397 —
VAT (l) 5.89 (2.10) 4.34 (1.83) <0.001 <0.001 5.93 (2.56) 0.937 0.434
Visceral fat index (l/m2) 2.06 (0.73) 1.52 (0.64) <0.001 <0.001 2.03 (0.84) 0.842 0.243
ASAT (l) 10.48 (4.90) 9.42 (4.86) 0.002 0.063 8.58 (3.93) 0.019 0.318
Abdominal fat index (l/m2) 5.87 (2.39) 4.93 (2.29) <0.001 <0.001 5.04 (1.92) 0.036 0.017




<0.001 <0.001 6.13 (2.77–
11.63)
0.160 0.999
MFI (%) 7.74 (2.57) 7.43 (1.95) 0.316 0.283 8.61 (2.29) 0.062 0.165
FFMV, l 10.40 (2.38) 11.43 (2.88) 0.001 <0.001 11.1 (2.34) 0.142 0.002
FFMVVCG, S.D.VCG 0.74 (1.71) 0.40 (1.14) <0.001 <0.001 0.31 (1.03) 0.052 <0.001
WMR (kg/l) 8.89 (1.95) 7.96 (1.99) <0.001 <0.001 8.03 (1.52) 0.006 <0.001
Values are mean (S.D.). For liver fat median (interquartile range).
aPsA vs MDF controls.
bPsA vs MDF controls adjusted for age, sex, and BMI.
cPsA vs Type 2 diabetes.
dPsA vs Type 2 diabetes adjusted for age, sex, and BMI.
ASAT: abdominal subcutaneous adipose tissue; FFMV: fat-free muscle volume; FFMVVCG: virtual control group (VCG)
adjusted FFMV; MFI: muscle fat infiltration; VAT: visceral adipose tissue; WMR: weight-to-muscle ratio.
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Fatty Liver Disease (NAFLD) prevalence observed in
psoriatic disease [15], linked in turn to hepatic insulin re-
sistance [4] and over twice the risk of diabetes com-
pared with those without NAFLD [16].
Of particular note, the reported body composition in
PsA is more strongly associated with type 2 diabetes,
and to a lesser degree CHD, compared with age, sex
and BMI-matched healthy individuals, consistent with
observational data [17]. Recent genetic studies have
suggested there is a causal link between adverse body
fat distribution and cardiometabolic outcomes [18], sug-
gesting that the PsA body composition may be causally
linked to such risks.
PsA participants also demonstrated lower thigh fat-
free muscle volume (FFMV) compared with MDF con-
trols. Previous work has shown an association between
lower FFMV with functional measures of low muscle
strength and poor physical performance characteristic
of sarcopenia [6]. There are little data on muscle volume
in PsA; however, a previous study demonstrated lower
skeletal muscle index and higher sarcopenia incidence
in PsA compared with controls without inflammatory
joint disease [19]. This may relate to decreased physical
activity secondary to joint pain and/or underlying chronic
inflammation.
Study strengths include that this is the first study to
compare detailed body composition parameters be-
tween PsA, healthy controls and type 2 diabetes using
the gold standard in body composition analysis, MRI.
By matching PsA individuals with healthy controls of
similar age, sex and BMI, we minimized covariate con-
founding. Limitations include cross-sectional study de-
sign and the modest number of PsA participants.
Results should be confirmed in a future study with a
larger number of PsA participants including those with
varying disease activity and biologic agent use. While
IMAPA imaging was conducted in a different centre to
UK Biobank, all images were obtained using standar-
dised AMRA protocols and analysed centrally by AMRA.
Further, between MR scanner bias and reproducibility
has recently been published and has shown that the
magnitude of any systematic differences between MR
scanners is smaller than the effect sizes observed in this
study, lending confidence that the findings we report are
genuine and robust [11].
In conclusion, individuals with PsA are metabolically
distinct with greater VAT and ectopic liver fat and lower
thigh muscle volume than age-, sex- and BMI-matched
healthy counterparts, and associated with greater pro-
pensity to CHD and type 2 diabetes. Indeed, PsA body
fat distribution was more in line with the pattern observed
in type 2 diabetes. These novel MRI findings suggest
that, as is the case in patients with type 2 diabetes,
weight loss should be a core component of PsA disease
management to lessen cardiometabolic risk. Large
randomized placebo-controlled trials are now needed to
prove weight loss improves body composition and out-
comes in PsA, as suggested by prior studies [20].
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